FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the chemical and pharmaceutical industry and is a method of obtaining a drug and the drug itself in the form of absorbable tablets of plant origin for the treatment of inflammatory diseases of the upper respiratory tract, containing as active substances levomenthol in the amount of 0.2500–0.6250 wt.%, eucalyptus leaf oil 0.05–0.0625 wt.%, peppermint pepper oil in terms of menthol 0–0.2500 wt.%, and as excipients in the amount of sucrose in the amount of 80.32–94.15 wt.%, sodium carmellose 1.0–5.0 wt.%, silicon dioxide colloidal 0.5–2.5 wt.%, talc 0.5–2.5 wt.%, stearic acid or its salts 0.40–1.0 wt.%, characterized in that it additionally contains beta-cyclodextrin in the amount of 3–10.0 wt. % and/or magnesium aluminometasilicate 1–10.0 wt.%.
EFFECT: group of inventions allows to obtain absorbable pectusin tablets with good disintegration for more than 15 minutes, as well as to increase the shelf life of the drug to 4 years.
8 cl, 2 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIMICROBIAL MEANS OF VEGETABLE ORIGIN AND METHOD OF OBTAINING IT | 2007 |
|
RU2354355C2 |
DOSAGE FORM FOR RELEASING DROTAVERINE IN ORAL CAVITY | 2019 |
|
RU2729659C1 |
TABLET CONTAINING 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE | 2014 |
|
RU2654703C2 |
ANTI-INFLAMMATORY COMPOSITION WITH PROLONGED ACTION FOR TREATING AIRWAY | 2015 |
|
RU2608126C1 |
MEDICINAL PREPARATION IN THE FORM OF TABLETS FOR PREVENTION AND / OR TREATMENT OF CATARRHAL, ACUTE RESPIRATORY AND OTHER INFECTIOUS-INFLAMMATORY DISEASES OF THROAT AND ORAL CAVITY | 2020 |
|
RU2741388C1 |
MODIFIED RELEASE DOSAGE FORM OF TRIMETAZIDINE DIHYDROCHLORIDE | 2009 |
|
RU2412706C1 |
LAXATIVE SOLID DOSAGE FORM AND METHOD FOR PREPARING THEREOF (VERSIONS) | 2009 |
|
RU2401106C1 |
MODIFIED-RELEASE THERAPEUTIC SYSTEMS FOR ORAL ADMINISTRATION OF MENTHOL IN THE TREATMENT OF INTESTINAL DISORDERS | 2014 |
|
RU2683645C1 |
PHARMACEUTICAL COMPOSITION CONTAINING BENZOCAINE WITH ENHANCED STABILITY | 2018 |
|
RU2761828C2 |
BIODEGRADABLE SYSTEM OF TRANSMUCOSAL DELIVERY OF DROTAVERIN | 2017 |
|
RU2699808C2 |
Authors
Dates
2018-12-21—Published
2017-09-28—Filed